Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Investor Lawsuit Over Alleged Wrgondoing In Acquisition By Takeda Pharmaceutical Company Limited Filed

If you purchased shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) and currently hold any of those NASDAQ:ARIA shares, you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to, or call us at (858) 779-1554.
Company Name(s): 
Ariad Pharmaceuticals
Case Name: 
Ariad Pharmaceuticals Deal Case 01/29/2017
Case Status: 
Lawsuit Filed
Affected Securities
Lawsuit Overview
Type of Lawsuit: 
Mergers and Acquisition
Date Filed: 

February 6, 2017 (Shareholders Foundation) - An investor who currently holds shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), filed a lawsuit in effort to halt the proposed takeover of Ariad Pharmaceuticals, Inc. by Takeda Pharmaceutical Company Limited for $24.00 per share.

The plaintiff alleges that the defendants breached their fiduciary duties owed to NASDAQ:ARIA stockholders by agreeing to sell Ariad Pharmaceuticals, Inc. too cheaply via an unfair process to W Takeda Pharmaceutical Company Limited.

On January 9, 2017, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced it has entered into an agreement to be acquired by Takeda Pharmaceutical Company Limited (TSE: 4502) under which Takeda Pharmaceutical Company will acquire all of the outstanding shares in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for $24.00 per share in cash, or a total enterprise value of approximately $5.2 billion,

However, plaintiff claims that the proposed consideration NASDAQ:ARIA shareholders will receive is grossly inadequate and undervalues Ariad Pharmaceuticals, Inc. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported that its annual Total Revenue increased from $105.41 million in 2014 to $118.80 million in 2015 and that its Net Loss grew from $162.60 million in 2014 to $231.16 million in 2015. In addition, the plaintiff alleges that the process is also unfair NASDAQ:ARIA stockholders.

On January 19, 2017, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) closed at $23.70 per share.